Sylvia Alarcon Velasco, MD
Hematology & Oncology · Wakefield, RINPI 1083097091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,152, 3.3 times the $346 reported in 2020.
Across 29 payments — averaging $64.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$252
- Incyte Corporation$234
- Rigel Pharmaceuticals, Inc.$162
- Sirtex Medical Inc$148
- Daiichi Sankyo Inc.$143
- E.r. Squibb & Sons, L.L.C.$140
- plus $793 from 14 others
What the payments were for
- Food & beverage$1,74793%
- Education$1257%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 3 | $252 |
| Incyte Corporation | 3 | $234 |
| Rigel Pharmaceuticals, Inc. | 2 | $162 |
| Sirtex Medical Inc | 1 | $148 |
| Daiichi Sankyo Inc. | 1 | $143 |
| E.r. Squibb & Sons, L.L.C. | 2 | $140 |
| AbbVie | 2 | $139 |
| Geron Corporation | 2 | $118 |
| Ipsen Biopharmaceuticals, Inc | 1 | $95 |
| Lilly USA, LLC | 1 | $94 |
| Eisai Inc. | 1 | $90 |
| Johnson & Johnson | 1 | $63 |
| Merck | 2 | $44 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Deciphera Pharmaceuticals Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $20 |
| GSK | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,872 in reported general payments places this provider in the 65th percentile of 68 hematology & oncology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 12 | $192,940 |
| EliquisApixaban | 16 | $11,240 |
| Ondansetron Hcl | 18 | $325 |
| Dexamethasone | 18 | $288 |
| Prochlorperazine Maleate | 25 | $277 |
| Prednisone | 12 | $102 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Wakefield
- Gerald ColvinWakefield$233K
- Griffin ReynoldsWakefield$5K
- James SmytheWakefield$2K
- Nancy McKinneyWakefield$313
- Jean LeeWakefield$246
- Tina RizackWakefield$147
- William SikovProvidence$156K
- Ritesh RathoreProvidence$148K
- Anthony MegaProvidence$65K
- Adam OlszewskiProvidence$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.